About Brightgene Bio-Medical Technology Co.,Ltd. Company

The company is an innovative pharmaceutical company participating in international competition. Driven by research and development, the company focuses on the first imitation, difficult to replicate, specialty APIs, complex formulations and original new drugs, and continues to build a high-tech barrier, gradually establishing a business system that integrates APIs and formulations, combines generic drugs with innovative drugs, and places equal emphasis on international and domestic markets, and is committed to meeting the unmet clinical needs of patients around the world. The company has always implemented a business system that integrates APIs and formulations, combines generic drugs with innovative drugs, and places equal emphasis on the international market and domestic market. Core products in the antiviral field include entecavir, oseltamivir, etc. Core products in the field of antifungal include capofungin, micafungin sodium, anifenzin, posaconazole, etc. Core products in the field of immunosuppression include everolimus, pimemecolus, etc., and core products in the field of respiratory system include budesonide, salmetroticasone, and tiotropium bromide. Core products in the field of anti-tumor include elibulin, innovative drug BGC0228, and innovative drug BGM0504. The company has successively won honors such as “National Intellectual Property Demonstration Enterprise” (awarded by the State Intellectual Property Office), “2017 China Patent Excellence Award” (awarded by the State Intellectual Property Office), “First Prize of the 11th Chinese Pharmaceutical Society Science and Technology Award”, “2021 Science and Technology Innovation Board Top 50 Value”, etc., and was selected for the “Shanghai Science and Technology Innovation Board 50 Component Index” sample and the honorary title of “Advanced Unit for Ecological and Environmental Protection”.